Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: Reversible with resumption of methotrexate without bosentan

Journal of Clinical Rheumatology

Volumn 15, Issue 2, 2009, Pages 88-89

  Dwyer, Nathan ^a   Jones, Graeme ^b   Kilpatrick, David ^a  

^a Department of Cardiology ^*  (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BOSENTAN; FISH OIL; FOLIC ACID; METHOTREXATE; MULTIVITAMIN; OMEPRAZOLE; PREDNISOLONE; SILDENAFIL; ANTIHYPERTENSIVE AGENT; DERMATOLOGICAL AGENT; SULFONAMIDE;

ADULT; ANOREXIA; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CASE REPORT; DETERIORATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; JAUNDICE; LETHARGY; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG ARTERY PRESSURE; MYOSITIS; NAUSEA; PRIORITY JOURNAL; PROGRESSIVE HAND ARTHROPATHY; PULMONARY HYPERTENSION; SCLERODERMA; TREATMENT OUTCOME; WALKING; DRUG INTERACTION; MIDDLE AGED; POLYPHARMACY; SYSTEMIC SCLEROSIS; TOXIC HEPATITIS;

ANTIHYPERTENSIVE AGENTS; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPERTENSION, PULMONARY; METHOTREXATE; MIDDLE AGED; POLYPHARMACY; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 67449085320     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31819bc71f     Document Type: Article

References (9)

1. Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-944.
2. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997;23: 883-915.
3. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354: 731-739.
4. Weber C, Gasser R, Hopfgartner G. Absorption, excretion and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999;27:810-815.
5. Dingemanse J, Van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43:1089-1115.
6. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645-648.
7. Bannwarth B, Pehourcq F, Schaeverkbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194-210.
8. Cozzi F, Ostuni PA, Marotta H, et al. Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate. Ann Rheum Dis. 2006;65:692-693.
9. Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78:165-171.